Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1545 • ACR Convergence 2021
Safety of JAK Inhibitor in Patients with Rheumatoid Arthritis Who Developed Reactivation of Herpes Zoster Virus After Receiving JAK Inhibitor
Wonho Choi¹, Soo Min Ahn², Yong Gil Kim¹, Chang-Keun Lee¹, Bin Yoo² and Seokchan Hong¹, ¹Asan Medical Center, Seoul, Republic of Korea, ²ASAN MEDICAL CENTER, Seoul, South Korea
Background/Purpose: Janus kinase inhibitor (JAKi) increases the risk of the reactivation of herpes zoster (HZ) virus and may thus be temporarily discontinued in cases of…
Abstract Number: 1658 • ACR Convergence 2021
Risk of Other Autoimmune Conditions Among Relatives of Patients with Rheumatoid Arthritis
Katherine Liao¹, Thany Seyok¹ and Lisa Cannon-Albright², ¹Brigham and Women's Hospital, Boston, MA, ²University of Utah School of Medicine, Salt Lake City, UT
Background/Purpose: Autoimmune conditions appear to cluster in families, as may be expected by shared genetic risk factors in conditions such as rheumatoid arthritis (RA), autoimmune…
Abstract Number: 1674 • ACR Convergence 2021
Effectiveness and Safety of Tofacitinib in Canadian Patients with RA: Primary Results from a Multicenter, Observational Study
Boulos Haraoui¹, Majed Khraishi², Denis Choquette¹, Larissa Lisnevskaia³, Michelle Teo⁴, Cassandra Kinch⁵, Corina Galos⁶, Patrice Roy⁵, David Gruben⁷, John C Woolcott⁸, Julie Vaillancourt⁹, John Sampalis¹⁰ and Edward Keystone¹¹, ¹Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ²Faculty of Medicine, Memorial University of Newfoundland, St. John’s, NL, Canada, ³Oshawa Clinic, Oshawa, ON, Canada, ⁴Penticton Regional Hospital, Penticton, BC, Canada, ⁵Pfizer Canada ULC, Kirkland, QC, Canada, ⁶Pfizer Canada ULC, Kirkland, SK, Canada, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Collegeville, PA, ⁹JSS Medical Research, Montréal, QC, Canada, ¹⁰McGill University and JSS Medical Research, Montréal, QC, Canada, ¹¹Keystone Consulting Enterprises Inc., Toronto, ON, Canada
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor (JAKi) for the treatment of RA. CANTORAL is the first large-scale, national, observational study assessing effectiveness and…
Abstract Number: 1690 • ACR Convergence 2021
Safety and Efficacy of Long-term Sarilumab Treatment in Patients with Active Rheumatoid Arthritis: EXTEND and MONARCH Open Label Extension Studies
Gerd Burmester¹, Vibeke Strand², Alan Kivitz³, Chih-Chi Hu⁴, Sheldon Wang⁴, Hubert van Hoogstraten⁵, Ray Tao⁶ and Roy Fleischmann⁷, ¹Charité University Medicine Berlin, Berlin, Germany, ²Stanford University School of Medicine, Portola Valley, CA, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Sanofi Genzyme, Bridgewater, NJ, ⁵Sanofi, Bridgewater, NJ, ⁶Sanofi China R&D, Shanghai, China (People's Republic), ⁷Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: In patients who experience intolerance or fail to respond to methotrexate, IL-6 receptor inhibitors (e.g. sarilumab) are one of the recommended options. The aim…
Abstract Number: 1707 • ACR Convergence 2021
A Bioengineered Probiotic for the Oral Delivery of an Immunomodulator in Rheumatoid Arthritis
Yuqing Wang¹, Duolong Zhu¹, Laura Ortiz-Velez², Jacob Perry¹, Michael Pennington³, Joseph Hyser¹, Robert Britton¹ and Christine Beeton¹, ¹Baylor College of Medicine, Houston, TX, ²TMC Innovation, Houton, ³AmbioPharm Inc., North Augusta, SC
Background/Purpose: CCR7- effector memory T (TEM) lymphocytes are targets for immunomodulation for the treatment of rheumatoid arthritis (RA). Following activation, TEM cells upregulate the expression…
Abstract Number: 1918 • ACR Convergence 2021
Don’t Forget About the Arthritis in RA-ILD! Impact of Pulmonary and RA Disease Severity on Survival
Rebecca Brooks¹, Joshua Baker², Yangyuna Yang¹, Punyasha Roul¹, Gail Kerr³, Andreas Reimold⁴, Gary Kunkel⁵, Katherine Wysham⁶, Namrata Singh⁷, Deana Lazaro⁸, Paul Monach⁹, Jill Poole¹, Dana Ascherman¹⁰, Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³Washington D.C., Veterans Affairs Medical Center (VAMC)/Georgetown and Howard Universities, Washington, DC, ⁴University of Texas – Southwestern Medical Center/Dallas Veterans Affairs Medical Center (VAMC), Dallas, TX, ⁵University of Utah, Salt Lake City, UT, ⁶VA Puget Sound/University of Washington, Seattle, WA, ⁷University of Washington, Bellevue, WA, ⁸VA New York Harbor Healthcare system, Brooklyn, NY, ⁹Brigham and Women's Hospital, Boston, MA, ¹⁰University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Long-term outcomes following a diagnosis of rheumatoid arthritis associated interstitial lung disease (RA-ILD) are poor, with a median survival estimated between 3 to 8…
Abstract Number: 0020 • ACR Convergence 2021
Citrullination Drives the Expression of Pro-fibrotic Genes in Rheumatoid Arthritis Fibroblast-like Cells
Peter Maloley, Evan Ryan, Nozima Aripova, Michael Duryee, Bryant England, Ted Mikuls and Geoffrey Thiele, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The pathophysiology of rheumatoid arthritis (RA) is hallmarked by joint inflammation, thickening of the pannus, and resultant joint destruction. Within the synovial tissue, citrullinated…
Abstract Number: 0037 • ACR Convergence 2021
Identification and Validation of Four Circulating Autoantibodies Associated with the ACPA Status in Early Rheumatoid Arthritis
Lucía Lourido¹, Cristina Ruiz-Romero², Lidia Collado¹, Monika Hansson³, Lars Klareskog⁴, Ronald Sjöberg⁵, Elisa Pin⁵, Peter Nilsson⁵ and Francisco Blanco-García⁶, ¹Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España., A Coruña, Spain, ²Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España.Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN). Av. Monforte de Lemos, 3-5. Pabellón 11, 28029, Madrid, España., A Coruña, Spain, ³Division for Rheumatology, Karolinska Institutet, Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁵Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology & SciLifeLab, Stockholm, Sweden, ⁶Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España.Universidade da Coruña (UDC), Grupo de Investigación de Reumatología y Salud (GIR-S). Departamento de Fisioterapia, Medicina y Ciencias Biomédicas, Facultad de Fisioterapia, Campus de Oza, 15008, A Coruña, España., A Coruña, Spain
Background/Purpose: The presence of anti-citrullinated protein antibodies (ACPAs) is a highly specific hallmark of rheumatoid arthritis (RA), that is present also in early disease. However,…
Abstract Number: 0110 • ACR Convergence 2021
Mortality in 2020 Due to COVID-19 in U.S. Adults with Rheumatic Diseases: Data from a Large, National, Multi-Rheumatic Disease Registry
Kaleb Michaud¹, Sofia Pedro², Rebecca Schumacher³, Mukund Kumar¹, Bryant England¹ and Alison Freifeld¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³Forward Databank, Wichita
Background/Purpose: Recent studies have detailed the excess death due to COVID-19 during the pandemic, yet few have examined these rates within a rheumatic disease population…
Abstract Number: 0181 • ACR Convergence 2021
Magnetic Resonance Imaging Findings in Early Rheumatoid Arthritis: Are There Differences Based on Autoantibody Status?
Caitrin Coffey¹, Gavin McKenzie¹, Nicholas Rhodes¹, Cassondra Hulshizer¹, Cynthia Crowson², John Davis¹ and Kerry Wright¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN
Background/Purpose: Magnetic resonance imaging (MRI) is increasingly used as an adjunct to the physical examination in early rheumatoid arthritis (RA). Characteristic differences in MRI findings…
Abstract Number: 0276 • ACR Convergence 2021
Pulse Pressure as a Predictor of Carotid Plaque in Rheumatoid Arthritis Patients
Natalia Guajardo-Jauregui, Iris Colunga-Pedraza, Jose Azpiri-Lopez, Dionicio Galarza-Delgado, Alejandra Rodriguez-Romero, Julieta Loya-Acosta, Alejandro Meza-Garza, Jesus Cardenas-de La Garza, Salvador Lugo-Perez and Jessica Castillo-Treviño, Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico
Background/Purpose: Pulse pressure (PP) is defined as the difference between systolic and diastolic blood pressure and represents arterial compliance and reflective properties of blood flow.…
Abstract Number: 0294 • ACR Convergence 2021
Comparison of Factors Associated with CT-Scan Progression of Interstitial Lung Disease in Rheumatoid Arthritis and Idiopathic Pulmonary Fibrosis. Retrospective Multicenter Study of 144 Patients
Charlotte Lucas¹, Aurore Tremblay¹, Thibaut Lapotre², Stéphane Jouneau³, Mathieu Lederlin² and Aleth Perdriger¹, ¹Rheumatology department, University Hospital, Rennes, France, ²Radiology Department, University Hospital, Rennes, France, ³Department of Respiratory Medicine, Competences Centre for Rare Pulmonary Diseases, Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France, Rennes, France
Background/Purpose: Compare factors associated with interstitial lung disease (ILD) progression determined on CT-scan analysis and survival in two distinct populations, patients with rheumatoid arthritis associated…
Abstract Number: 0512 • ACR Convergence 2021
Peficitinib and Filgotinib Inhibit Angiogenesis via Suppression of VEGF Production in Rheumatoid Arthritis Fibroblast-like Synoviocytes
Yuzo Ikari, Takeo Isozaki, Kuninobu Wakabayashi and Tsuyoshi Kasama, Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
Background/Purpose: Peficitinib and filgotinib are novel Janus kinase (JAK) inhibitors developed for the treatment of rheumatoid arthritis (RA). Peficitinib inhibits all JAKs, especially JAK3. Filgotinib,…
Abstract Number: 0576 • ACR Convergence 2021
Associations of the MUC5B Promoter Variant with Timing of Articular Diagnosis and Interstitial Lung Disease in Rheumatoid Arthritis
Gregory McDermott¹, Ritu Gill², Staci Gagne³, Suzanne Byrne³, Weixing Huang³, Jing Cui⁴, Lauren Prisco⁵, Alessandra Zaccardelli³, Lily Martin³, Nancy Shadick⁶, Paul Dellaripa³, Tracy Doyle⁷ and Jeffrey Sparks³, ¹Brigham and Women's Hospital, Brookline, MA, ²Beth Israel Deaconess Medical Center, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Pound Ridge, MA, ⁶Brigham & Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital, West Roxbury, MA
Background/Purpose: The common promoter variant of MUC5B (G >T, rs35705950) is associated with increased mucin 5B production in lung parenchyma and is an established genetic…
Abstract Number: 0606 • ACR Convergence 2021
How Might We Care for Rheumatoid Arthritis (RA) Patients Unable to See a Rheumatologist And/or Use Certain of Our Medications? Proposed Preliminary Recommendations for RA Patients Who Don’t Meet Our Established Guidelines
Nicole Zagelbaum Ward¹, Abhimanyu Amarnani¹, Baljeet Rai², Corinne Feldman¹, Brett Feldman¹ and Richard Panush¹, ¹LAC+USC Medical Center, Los Angeles, CA, ²LAC USC, Los Angeles, CA
Background/Purpose: Physicians share responsibilities to promote social justice and assure equitable healthcare for all. Street medicine (SM) is a field dedicated to address the need…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].